Chiesi Buys KalVista for $1.9 Billion in Biggest Deal Yet to Strengthen Rare Disease Portfolio

Chiesi will buy KalVista for $1.9B to get EKTERLY, a new oral rare disease drug, and grow its global rare disease business.